Reporting Concerns
Applied Clinical Trials
Drug safety has become a significant issue to many portions of society. High visibility issues like the Vioxx litigation have no doubt increased that salience among the general public. Moreover, with changing demographics, economic trends, and wider numbers of medical applications of prescription drugs, usage of these drugs will only increase, as will the accompanying issue of drug safety.
Drug safety has become a significant issue to many portions of society. High visibility issues like the Vioxx litigation have no doubt increased that salience among the general public. Moreover, with changing demographics, economic trends, and wider numbers of medical applications of prescription drugs, usage of these drugs will only increase, as will the accompanying issue of drug safety.
There is a noteworthy uneasiness among some U.S. clinical investigators about the reporting systems associated with serious adverse events (SAE) in clinical trials. Among the challenges of running clinical studies, SAE reporting received the highest mention in this random sample of over 1000 investigators, regardless of whether the investigator site was a dedicated research organization or not, or whether the investigator was highly experienced or not.
Investigator Dissatisfaction with Clinical Trial Activity
Clinical investigators may be more sensitive to the general issue of drug safety because others have given such attention. For example, the Institute of Medicine highlighted the difficulty of anticipating possible drug safety issues with marketed drugs based upon the relatively small number of patients taking part in clinical research studies.
Investigator unease with SAE reporting may open other questions for sponsors. For instance, clinical investigators who feel uncomfortable with drug safety reporting may become more reluctant to allow their patients to participate in trials.—TTC (For more information, please contact help@ttc-llc.com.)
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
